tiprankstipranks
Trending News
More News >
Clene (CLNN)
NASDAQ:CLNN
Advertisement

Clene (CLNN) AI Stock Analysis

Compare
1,059 Followers

Top Page

CLNN

Clene

(NASDAQ:CLNN)

Rating:54Neutral
Price Target:
$5.50
▼(-2.83% Downside)
Clene's overall stock score is primarily impacted by its financial instability, with significant losses and negative equity. However, positive technical indicators and recent corporate events, such as regulatory updates and Nasdaq compliance, provide some optimism. The valuation remains weak due to negative earnings and lack of dividends.
Positive Factors
Financial Stability
Clene has sufficient cash balance to fund operations into the next year and is well-positioned to raise additional capital for NDA filing, providing financial stability for upcoming milestones.
Regulatory Approval
The Orphan Drug Designation for CNM-Au8 should qualify it for Priority Review by the FDA, suggesting a faster review process and potential for quicker market entry.
Regulatory Engagement
Clene continues meaningful engagement with the FDA, which appears to not have been impacted by changes at the agency.
Negative Factors
Cash Position
CLNN ended 1Q25 with a cash position of $9.8M, which provides a cash runway into 3Q25.
Earnings
Clene announced 2Q25 results, posting EPS of ($0.78), compared to estimate of ($0.39), and consensus of (0.46).

Clene (CLNN) vs. SPDR S&P 500 ETF (SPY)

Clene Business Overview & Revenue Model

Company DescriptionClene Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, primarily targeting conditions such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The company operates in the biotechnology sector, leveraging its proprietary nanotechnology platform to create drug candidates that aim to restore cellular function and improve patient outcomes. Clene’s core products include CNM-Au8, a gold nanocrystal suspension designed to enhance cellular energy metabolism and protect neuronal health.
How the Company Makes MoneyClene generates revenue primarily through the development and commercialization of its therapeutic products. The company makes money by advancing its drug candidates through clinical trials, which can lead to licensing agreements, partnerships with larger pharmaceutical companies, and potential product sales once therapies receive regulatory approval. Key revenue streams include milestone payments from collaborations, royalties on future sales, and funding from government grants or research institutions. Additionally, partnerships with academic institutions and biopharmaceutical firms may provide financial support and shared expertise that enhance its revenue-generating capabilities.

Clene Financial Statement Overview

Summary
Clene is facing considerable financial challenges with declining revenues, high net losses, and negative equity. The substantial operating losses and cash flow issues highlight the need for strategic restructuring or additional capital infusion. The biotechnology sector's inherent risk is amplified by Clene's financial instability.
Income Statement
30
Negative
Clene has experienced significant revenue fluctuations with a decline from $654,000 in 2023 to $342,000 in 2024, reflecting a -47.71% revenue growth rate. The gross profit margin is relatively strong at 79.53%, but the company has negative net profit and EBIT margins due to substantial losses, with a net loss of $39.4 million in 2024.
Balance Sheet
20
Very Negative
The company has a negative stockholders' equity of -$8.86 million, indicating financial distress. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total debt of $20.84 million suggests significant leverage. With equity being negative, the equity ratio is also negative, signaling potential insolvency risks.
Cash Flow
35
Negative
Operating cash flow remains deeply negative at -$21.33 million, with a slightly improved free cash flow position over the year. The free cash flow to net income ratio indicates severe cash burn issues, and financing cash flow has decreased, showing potential challenges in raising capital.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue286.00K342.00K654.00K473.00K723.00K206.00K
Gross Profit230.00K272.00K533.00K447.00K434.00K141.00K
EBITDA-29.64M-33.69M-43.24M-25.21M-8.22M-16.92M
Net Income-29.70M-39.40M-49.50M-15.28M-9.74M-19.28M
Balance Sheet
Total Assets22.13M27.34M52.34M44.49M63.06M68.24M
Cash, Cash Equivalents and Short-Term Investments7.29M12.15M35.00M23.32M50.29M59.27M
Total Debt20.85M20.84M32.16M31.82M24.04M4.32M
Total Liabilities30.68M36.19M38.95M41.26M50.47M67.90M
Stockholders Equity-8.55M-8.86M13.39M3.24M12.60M341.00K
Cash Flow
Free Cash Flow-17.64M-21.34M-30.50M-44.19M-35.96M-19.32M
Operating Cash Flow-17.64M-21.33M-30.17M-39.01M-34.62M-18.93M
Investing Cash Flow-3.00K6.32M-1.50M-10.16M-1.33M-387.00K
Financing Cash Flow3.27M-1.53M42.16M17.25M27.11M69.53M

Clene Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.66
Price Trends
50DMA
3.94
Positive
100DMA
3.50
Positive
200DMA
4.05
Positive
Market Momentum
MACD
0.38
Negative
RSI
77.55
Negative
STOCH
92.58
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLNN, the sentiment is Positive. The current price of 5.66 is above the 20-day moving average (MA) of 3.97, above the 50-day MA of 3.94, and above the 200-day MA of 4.05, indicating a bullish trend. The MACD of 0.38 indicates Negative momentum. The RSI at 77.55 is Negative, neither overbought nor oversold. The STOCH value of 92.58 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLNN.

Clene Risk Analysis

Clene disclosed 66 risk factors in its most recent earnings report. Clene reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Clene Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
$20.91B14.58-4.08%3.07%2.70%-8.71%
54
Neutral
$53.35M-1738.36%-35.29%45.18%
46
Neutral
$28.60M-422.64%129.20%30.36%
44
Neutral
$30.17M-112.22%
34
Underperform
$31.43M-44.71%44.85%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CLNN
Clene
5.66
0.07
1.25%
DYAI
Dyadic International
0.85
-0.59
-40.97%
AKTX
Akari Therapeutics
0.92
-2.88
-75.79%
ANTX
AN2 Therapeutics, Inc.
1.15
0.01
0.88%

Clene Corporate Events

Private Placements and FinancingFinancial Disclosures
Clene Amends Notes and Secures New Financing
Neutral
Aug 14, 2025

On August 13, 2025, Clene Inc. announced amendments to its December 2024 senior secured convertible promissory notes, extending the maturity date to February 13, 2027, and postponing the commencement of monthly principal repayments to September 13, 2026. Additionally, the company entered into a new note purchase agreement with AE Capital Limited and others, issuing $1.5 million in senior secured convertible promissory notes. These financial maneuvers aim to provide Clene with a cash runway into the first quarter of 2026, supporting its ongoing clinical programs. Clene also reported its second quarter 2025 financial results, highlighting a net loss of $7.4 million and cash reserves of $7.3 million as of June 30, 2025. The company is advancing its CNM-Au8 programs for ALS and MS, with significant FDA meetings scheduled for the third quarter of 2025, aiming for a new drug application submission for ALS by the end of 2025.

Private Placements and FinancingRegulatory Filings and Compliance
Clene Files Prospectus for Additional Share Offering
Neutral
Jul 3, 2025

On April 28, 2025, Clene Inc. entered into an equity distribution agreement with Canaccord Genuity LLC to offer and sell shares of its common stock, aiming to raise up to $25 million. By July 3, 2025, Clene had filed a prospectus supplement for an additional $2,015,000 in shares, indicating ongoing efforts to secure funding for its operations and potentially strengthen its market position.

Product-Related AnnouncementsRegulatory Filings and Compliance
Clene Announces Regulatory Update After FDA Meeting
Positive
Jun 30, 2025

On June 30, 2025, Clene Inc. announced a regulatory update following a constructive Type C meeting with the FDA regarding its neurofilament biomarker analysis plan. The FDA provided supportive feedback on Clene’s proposed statistical analysis plan for its NIH-sponsored Expanded Access Program, which supports ALS patients treated with CNM-Au8®. The company plans to conduct neurofilament light (NfL) biomarker analyses early in the fourth quarter of 2025 and aims to submit a new drug application for ALS under the accelerated approval pathway by the end of 2025. Additionally, Clene confirmed two more FDA meetings in the third quarter of 2025 to discuss ALS survival data and the MS clinical development program, which could further advance its ALS and MS therapeutic initiatives.

Delistings and Listing ChangesRegulatory Filings and Compliance
Clene Regains Nasdaq Compliance as of June 2025
Positive
Jun 17, 2025

On June 17, 2025, Clene Inc. announced that it has regained compliance with Nasdaq Listing Rule 5550(b)(2), as its market value of listed securities has been $35.0 million or greater for 10 consecutive business days from June 2 to June 16, 2025. This compliance ensures Clene’s continued listing on Nasdaq, closing the matter and potentially stabilizing its market position.

Executive/Board ChangesShareholder MeetingsStock Split
Clene Approves Stock Plan Amendment at Annual Meeting
Neutral
May 23, 2025

On May 22, 2025, Clene Inc. held its Annual Meeting of Stockholders, where the stockholders approved an amendment to the company’s 2020 Stock Plan, increasing the number of shares of common stock reserved for issuance by 800,000 shares. Additionally, the Board of Directors approved an amendment to the compensation program for nonemployee directors, adjusting stock option grants to reflect a reverse stock split from July 2024. These changes are expected to impact the company’s stock management and director compensation structure, potentially affecting shareholder value and governance practices.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 21, 2025